AKT1 and cancer: Compared with FMN, the hybrid product could significantly inhibit the growth and migration of gastric cancer SGC7901 cells through the wnt/β-Catenin and AKT/mTOR pathways, and could be used as an inhibitor of SIRT1 to inhibit its expression, thereby inducing cancer cell death.